ArticleJournal of neurology2010
Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.
Article in Journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 5 syntheses or guidelines pooled it, 289 citations in OpenAlex.
- BDNF and GDNF in Parkinson's Disease: Associations with Clinical Features, Disease Course, and Progression-A Systematic Review.Molecular neurobiology · 2026Pooled it
- Association of brain-derived neurotrophic factor in blood and cerebrospinal fluid with Parkinson's disease and non-motor symptoms of Parkinson's disease: a systematic review and meta-analysis of 6655 participants.Frontiers in aging neuroscience · 2025Pooled it
- Changes of brain-derived neurotrophic factor (BDNF) levels after different exercise protocols: a systematic review of clinical studies in Parkinson's disease.Frontiers in physiology · 2024Pooled it
- The Effect of Endurance Training on Brain-Derived Neurotrophic Factor and Inflammatory Markers in Healthy People and Parkinson's Disease. A Narrative Review.Frontiers in physiology · 2020Pooled it
- Association of Levels of Physical Activity With Risk of Parkinson Disease: A Systematic Review and Meta-analysis.JAMA network open · 2018Pooled it
- Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease.Inflammopharmacology · 2025Trial
- Changes in proBDNF and Mature BDNF Levels After Medium-Intensity Functional Motor Rehabilitation Program in Patients with Parkinson's Disease.International journal of molecular sciences · 2025Trial
- The Effects of FermentedEvidence-based complementary and alternative medicine : eCAM · 2018Trial
- Growth factor applications and clinical translation: advances and challenges.Annals of medicine · 2026Review
- Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.Signal transduction and targeted therapy · 2026Review
- Inhibition of Abnormal Elevated α-Synuclein Ameliorates Dopaminergic Neuron Degeneration in Parkinson's Disease Mouse Model.Aging cell · 2026Article
- Serum BDNF as an Objective Indicator of Rehabilitation Response in Patients with Subacute Stroke.Journal of clinical medicine · 2026Article
- Moderate hypoxaemia and cognitive impairment in individuals with cigarette smoke exposure.ERJ open research · 2026Article
- Neuromodulatory Effects of Substantia Nigra Pars Reticulata Deep Brain Stimulation (SNr-DBS) in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Acupuncture: A Promising Non-Pharmacological Approach to Parkinson's Disease Management.Brain and behavior · 2026Review
- ASL/ALT Ratio in Familial and Sporadic Parkinson's Disease: Insights From Cross-Sectional Logistic Analysis.Brain and behavior · 2026Article
- Machine-Learning-Based Targeted Plasma Proteomic Analysis for Predicting Motor Progression in Parkinson's Disease: An Interpretable Approach to Personalized Disease Management.Bioengineering (Basel, Switzerland) · 2026Article
- Article
- Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerative Diseases: A Comprehensive Review.Drug design, development and therapy · 2026Review
- Intensive multidisciplinary rehabilitation modulates serumFrontiers in cellular neuroscience · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The brain-derived neurotrophic factor (BDNF) is a potent inhibitor of apoptosis-mediated cell death and neurotoxin-induced degeneration of dopaminergic neurons. There is a growing body of evidence implicating BDNF in the pathogenesis of Parkinson's disease (PD), suggesting it may eventually be used in the development of neuroprotective therapies for PD. The serum BDNF of 47 PD patients and of 23 control subjects was assessed, and serum BNDF levels were significantly decreased in PD patients when compared with controls (p = 0.046). Interestingly enough, BDNF correlated positively with a longer time span of the disease, as well as with the severity of the PD symptoms and with more advanced stages of the disease. Additionally, higher BDNF levels also correlated with poor balance as assessed by the Berg Balance Scale, more time spent at the Timed Up & Go Test, reduced speed of gait and shorter distance walked during the Six-Minute Walk Test. Our results corroborate the literature regarding the involvement of BDNF in PD. We hypothesize that lower BDNF levels in early stages of the disease may be associated with pathogenic mechanisms of PD. The increase of BDNF levels with the progression of the disease may be a compensatory mechanism in more advanced stages of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.